Immunitybio is trading 4.8% lower at $9.52, with biotech-sector weakness the clearest supporting context but no confirmed company-specific negative catalyst.
- XBI was reported down 2.06%, consistent with pressure on the stock, but this does not establish the cause of the intraday move.
- The FDA’s ANKTIVA label expansion announced October 14 was a positive company development, not an explanation for the decline.
- Search results contained conflicting price-direction reports; the supplied live price is used.